Gene Therapy for Muscular Disorders

Kongressthemen
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/1443975-3?pid=4832

Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo and More

https://go.evvnt.com/1443975-2?pid=4832

Frau Emily Birt